evidence table
Inositol Metabolic Health Meta-Analysis Evidence Table
Structured evidence table for Inositol Metabolic Health Meta-Analysis, generated from 2 reusable source documents in the Migaku knowledge base.
| topic | claim | evidence level | citation | source |
|---|---|---|---|---|
| Inositol Metabolic Health Meta-Analysis | Objectives This umbrella review aimed to synthesize and appraise the evidence regarding the efficacy of inositol for Polycystic Ovary Syndrome (PCOS) by integrating meta-analyses of randomized controlled trials(RCTs), thereby assessing the robustness of the existing body of evidence. | 2 | Duan M (2026) | Effects of inositol in women with polycystic ovary syndrome: an umbrella review of meta-analyses from randomized controlled trials. |
| Inositol Metabolic Health Meta-Analysis | GRADE assessment of 85 evidence items revealed no high-quality evidence; 18.9% were moderate, 40% low, and 41.1% very low quality. | 2 | Duan M (2026) | Effects of inositol in women with polycystic ovary syndrome: an umbrella review of meta-analyses from randomized controlled trials. |
| Inositol Metabolic Health Meta-Analysis | Pooled analyses demonstrated that inositol significantly improved multiple outcomes compared to placebo/FA: it reduced serum luteinizing hormone (LH: MD -3.43 IU/L, 95% CI [-4.29, -2.56], P P P P P P = 0.03; ovulation rate: RR 2.75, 95% CI [1.71, 4.41], P Conclusion Inositol improves core PCOS manifestations. | 2 | Duan M (2026) | Effects of inositol in women with polycystic ovary syndrome: an umbrella review of meta-analyses from randomized controlled trials. |
| Inositol Metabolic Health Meta-Analysis | Methods We searched four databases from inception to August 2025 for relevant RCT meta-analyses. | 2 | Duan M (2026) | Effects of inositol in women with polycystic ovary syndrome: an umbrella review of meta-analyses from randomized controlled trials. |
| Inositol Metabolic Health Meta-Analysis | In addition to reproductive complications, PCOS is associated with several metabolic and systemic consequences (,). | 3 | Aydin Cil Mevra (2026) | Two decades of nutrition research in polycystic ovary syndrome: emerging patterns and scientific output (2004–2024) |
| Inositol Metabolic Health Meta-Analysis | At this point, PCOS is associated with an increased risk for developing reproductive, metabolic, cardiovascular, oncological, and psychological disturbances (). | 3 | Aydin Cil Mevra (2026) | Two decades of nutrition research in polycystic ovary syndrome: emerging patterns and scientific output (2004–2024) |
| Inositol Metabolic Health Meta-Analysis | Meta-analyses have revealed that women with PCOS exhibit a greater prevalence of cardiometabolic risk factors that increase long-term healthcare costs, including metabolic syndrome, type 2 diabetes mellitus, dyslipidemia/hyperlipidemia, hypertension, and chronic low-grade inflammation (,). | 3 | Aydin Cil Mevra (2026) | Two decades of nutrition research in polycystic ovary syndrome: emerging patterns and scientific output (2004–2024) |
| Inositol Metabolic Health Meta-Analysis | 1 2 3 2–4 5 6 Polycystic ovary syndrome (PCOS) is among the most prevalent endocrine disorders in women of reproductive age, affecting approximately one in five women. | 3 | Aydin Cil Mevra (2026) | Two decades of nutrition research in polycystic ovary syndrome: emerging patterns and scientific output (2004–2024) |
Source documents